Tensha Gets Funding To Advance Projects | Chemical & Engineering News
Volume 89 Issue 38 | p. 17 | Concentrates
Issue Date: September 19, 2011

Tensha Gets Funding To Advance Projects

Department: Business
Keywords: epigenetics, drug discovery, cancer

Tensha Therapeutics, a Cambridge, Mass.-based epigenetics start-up, has gotten $15 million from HealthCare Ventures, a venture capital firm that invests in preclinical and early clinical stage firms. Founded on research out of the Dana-Farber Cancer Institute, Tensha is developing small-molecule bromodomain inhibitors to treat cancer and other diseases. Bromodomains are epigenetic drug targets that play critical roles in regulating the transcription of disease-associated genes. HealthCare Ventures plans to support Tensha’s compound development to the clinical proof-of-concept stage.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment